Opus Genetics Highlights Significant Progress in 2025 and Upcoming Catalysts in 2026
Opus Genetics highlighted its progress achieved during 2025 and upcoming catalysts in 2026. OPGx-BEST1: First participant dosed in Phase 1/2 trial with enrollment ongoing. Initial data expected this quarter at Macula Society with 3-month results from the entire Cohort 1 expected in mid-2026. OPGx-BEST1 is potentially eligible for multiple regulatory designations which the Company expects to file for in 2026. OPGx-LCA5: Enrollment ongoing in run-in period for planned, adaptive pivotal Phase 3 trial. Dosing with OPGx-LCA5 in the Phase 3 trial expected in the second half of 2026. Pre-Clinical Gene Therapy Pipeline: Multiple partnerships with patient advocacy organizations are increasing awareness in the IRD community and providing non-dilutive funding for pre-clinical testing of Opus Genetics gene therapy pipeline. Phentolamine Ophthalmic Solution 0.75%: Supplemental New Drug Application submitted for the treatment of presbyopia, with an anticipated regulatory decision by the end of 2026. LYNX-3, the second pivotal Phase 3 trial in keratorefractive participants with visual disturbances under mesopic, low-contrast conditions, is ongoing with topline results expected in the first half of 2026.
Trade with 70% Backtested Accuracy
Analyst Views on IRD
About IRD
About the author
Opus Genetics Insider Cam Gallagher Acquires 164,000 Shares of IRD for $323,693
- Insider Purchase: Cam Gallagher of Opus Genetics acquired 164,000 shares of IRD at $1.97 each on Wednesday, totaling an investment of $323,693, reflecting confidence in the company's future prospects.
- Investment Return: Gallagher's investment is currently up approximately 18.1%, based on today's trading high of $2.33, indicating a positive market response and potential growth outlook for IRD.
- Market Performance: Opus Genetics shares rose about 8.7% on Friday, reflecting optimistic sentiment among investors regarding the company's outlook, potentially driven by Gallagher's purchase.
- CEO Acquisition: Additionally, CEO Dwayne L. Hyzak purchased 3,712 shares of MSC Income Fund at $13.43 each for a total of $49,852, demonstrating ongoing confidence in the fund's performance.
Opus Genetics Grants 50,000 Stock Options to Attract New Employee
- Equity Incentive Plan: Opus Genetics approved an equity award of 50,000 stock options to a new employee under its 2021 Inducement Plan, aimed at attracting top talent and strengthening its team to drive innovation in gene therapy.
- Option Details: The options have an exercise price equal to the fair market value of the company's common stock on the grant date, vesting over four years with 25% vesting after one year and the remaining 75% in quarterly installments, ensuring long-term employee retention aligned with company goals.
- Compliance Assurance: This equity award complies with Nasdaq Listing Rule 5635(c)(4), ensuring that the company adheres to transparent compliance procedures while attracting talent, thereby enhancing investor confidence.
- Company Background: Opus Genetics focuses on developing gene therapies to restore vision for patients with inherited retinal diseases, with a pipeline of seven AAV-based programs, showcasing the company's strong R&D capabilities and market potential in the biopharmaceutical sector.
